| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.8 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.8 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |